Search results for "BRCA1"

showing 10 items of 65 documents

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

2014

Introduction More than 70 common alleles are known to be involved in breast cancer (BC) susceptibility, and several exhibit significant heterogeneity in their associations with different BC subtypes. Although there are differences in the association patterns between BRCA1 and BRCA2 mutation carriers and the general population for several loci, no study has comprehensively evaluated the associations of all known BC susceptibility alleles with risk of BC subtypes in BRCA1 and BRCA2 carriers. Methods We used data from 15,252 BRCA1 and 8,211 BRCA2 carriers to analyze the associations between approximately 200,000 genetic variants on the iCOGS array and risk of BC subtypes defined by estrogen re…

Cancer ResearchReceptor ErbB-2Genes BRCA2BRCALOCIGenes BRCA1MODIFIERSVARIANTSErbB-2610 Medical sciences MedicineDuctalReceptorsMedicine and Health SciencesINVESTIGATORSBreastskin and connective tissue diseasesProgesteroneMedicine(all)Carcinoma Ductal BreastMiddle AgedAdult; Aged; Alleles; Breast Neoplasms; Carcinoma; Carcinoma Ductal Breast; Carcinoma Lobular; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Genes BRCA1; Genes BRCA2; Cancer Research; OncologyOncologyReceptors EstrogenTUMOR SUBTYPESFemaleReceptors ProgesteroneReceptorResearch ArticleAdultHeterozygote610Breast NeoplasmsMEDULLARY CARCINOMAOVARIAN-CANCERLobularHumansGenetic Predisposition to DiseaseGENOME-WIDE ASSOCIATIONAllelesAgedNeoplasm StagingAdult; Aged; Alleles; Breast Neoplasms; Carcinoma; Carcinoma Ductal Breast; Carcinoma Lobular; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Genes BRCA1; Genes BRCA2CONSORTIUMCarcinomaBRCA1EstrogenBRCA2Carcinoma LobularESTROGEN-RECEPTORGenesNeoplasm GradingBreast Cancer Research
researchProduct

Prevalencia de mutaciones patogénicas de los genes BRCA1 y BRCA2 en pacientes con cáncer de mama esporádico. Puesta a punto de un método de cribado b…

2015

INTRODUCCIÓN: El cáncer de mama (CM) es la principal causa de morbimortalidad en la mujer con una incidencia mundial de 1.384.155 casos nuevos por año [1]. Aproximadamente, entre el 5-15% de los CM responden al síndrome del cáncer de mama y de ovario hereditario (CMOH) que se debe principalmente a la presencia de mutaciones en los genes BRCA1 (AY273801.1, GI: 30039658) [2] y BRCA2 (AY436640.1 GI: 37675288) [3], (BRCA1/2). La herencia de una única mutación en cualquiera de estos dos genes confiere un riesgo de entre el 45-85% de desarrollar CM a lo largo de la vida [5,6]; sin embargo, la prevalencia real de las mutaciones BRCA1/2 no se conoce al haber sido tan sólo estudiadas en población de…

Cáncer de MamaUNESCO::CIENCIAS DE LA VIDABRCA1BRCA2HRM:CIENCIAS DE LA VIDA [UNESCO]
researchProduct

RAB3GAP1 and RAB3GAP2 modulate basal and rapamycin-induced autophagy

2014

Macroautophagy is a degradative pathway that sequesters and transports cytosolic cargo in autophagosomes to lysosomes, and its deterioration affects intracellular proteostasis. Membrane dynamics accompanying autophagy are mostly elusive and depend on trafficking processes. RAB GTPase activating proteins (RABGAPs) are important factors for the coordination of cellular vesicle transport systems, and several TBC (TRE2-BUB2-CDC16) domain-containing RABGAPs are associated with autophagy. Employing C. elegans and human primary fibroblasts, we show that RAB3GAP1 and RAB3GAP2, which are components of the TBC domain-free RAB3GAP complex, influence protein aggregation and affect autophagy at basal an…

GTPase-activating proteinlipid dropletsrab3 GTP-Binding ProteinsATG16L1DMSO dimethyl sulfoxideFEZ20302 clinical medicineATG autophagy-relatedPhagosomesDAPI 4’ 6-diamidino-2-phenylindoleSQSTM1 sequestosome 1ATG16L1MAP1LC3 microtubule-associated protein 1 light chain 3GFP green fluorescent protein0303 health sciencesGABARAP GABA(A) receptor-associated proteinGTPase-Activating ProteinsCell biologyRAB3GAP1RAB3GAP2RABGAP RAB GTPase activating proteinATG3autophagyCALCOCO2 calcium binding and coiled-coil domain 2Basic Research PaperseV empty vectorATG8ATG5PBS phosphate-buffered salineBiologyPE phosphatidylethanolamineTBC domain TRE2-BUB2-CDC16 domainBAG3GEF guanine nucleotide exchange factor03 medical and health sciencesC. elegans Caenorhabditis elegansAnimalsHumansCaenorhabditis elegansMolecular Biology030304 developmental biologySirolimusDPH 1 6-diphenyl-1 3 5-hexatrieneproteostasisAutophagyBiological TransportCell BiologyFEZ1Bafi bafilomycin A1FEZ fasciculation and elongation protein zetaNBR1 neighbor of BRCA1 gene 1ProteostasissiRNA small interfering RNABSA bovine serum albuminRabLysosomes030217 neurology & neurosurgeryAutophagy
researchProduct

Founder mutations in BRCA1 and BRCA2 genes

2007

BRCA1 and BRCA2 germline mutations contribute to a significant number of familial and hereditary breast and/or ovarian cancers. The proportion of high-risk families with breast and/or ovarian cancer cases due to mutations in these tumor suppressor genes varies widely among populations. In some population, a wide spectrum of different mutations in both genes are present, whereas in other groups specific mutations in BRCA1 and BRCA2 have been reported with high frequency. Most of these mutations are prevalent in restricted populations as consequence of a founder effect. The comparison of haplotypes between families with the same mutation can distinguish whether high-frequency alleles derive f…

Genetic counselingPopulationBiologymedicine.disease_causeGermline mutationEthnicitymedicineHumansGenetic TestingeducationGenetic testingBRCA2 ProteinGeneticseducation.field_of_studyMutationmedicine.diagnostic_testBRCA1 ProteinHaplotypeHematologyPenetranceFounder EffectOncologyMutationApoptosis Regulatory ProteinsBRCA1 BRCA2 founder mutationFounder effect
researchProduct

Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines

2013

Previously, it has been reported that hypoxia causes increased mutagenesis and alteration in DNA repair mechanisms. In 2005, an interesting study showed that hypoxia-induced decreases in BRCA1 expression and the consequent suppression of homologous recombination may lead to genetic instability. However, nothing is yet known about the involvement of BRCA2 in hypoxic conditions in breast cancer. Initially, a cell proliferation assay allowed us to hypothesize that hypoxia could negatively regulate the breast cancer cell growth in short term in vitro studies. Subsequently, we analyzed gene expression in breast cancer cell lines exposed to hypoxic condition by microarray analysis. Interestingly,…

Genome instabilityDNA RepairArticle SubjectDNA repairDNA damageSettore MED/06 - Oncologia MedicaDown-Regulationlcsh:MedicineBreast NeoplasmsBiologyGeneral Biochemistry Genetics and Molecular BiologyGenomic InstabilityBreast cancerCell Line TumorBreast CancermedicineHumansEnzyme Inhibitorsskin and connective tissue diseasesHypoxiaBiologyGeneral Immunology and MicrobiologyBRCA1 ProteinGenome Humanlcsh:RGenome StabilityGeneral MedicineDNA repair protein XRCC4medicine.diseaseBRCA2Cell HypoxiaAmino Acids DicarboxylicGene Expression Regulation NeoplasticCancer researchDNA mismatch repairFemaleHuman medicineHypoxia; Genome Stability; BRCA2; Breast CancerHomologous recombinationEngineering sciences. TechnologyNucleotide excision repairResearch ArticleDNA Damage
researchProduct

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

2016

Background BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). Methods We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (…

Male0301 basic medicineGenotype-phenotype correlationPathologygenotype-phenotype correlationsendocrine system diseasesSettore MED/06 - Oncologia MedicaFEATURESmale breast cancerGenotype-phenotype correlationsLogistic regressionHistologic grade610 Medical sciences MedicineBreast cancer0302 clinical medicineEpidemiologyMedicine and Health SciencesPathologypolycyclic compoundsskin and connective tissue diseasesPOPULATIONRISKeducation.field_of_studyBRCA1 ProteinMenSingle NucleotideMiddle Aged3. Good healthGRADE030220 oncology & carcinogenesisMale breast canceroncologyFemaleBreast NeoplasmResearch ArticleHumanAdultmedicine.medical_specialtyCARCINOMAGenotype–phenotype correlations3122 CancersPopulation610Breast NeoplasmsBRCA1/2; genotype-phenotype correlations; histologic grade; male breast cancer; pathology; cancer research; oncologyMale breast cancer BRCA1 BRCA2Polymorphism Single NucleotideCàncer de mamaBreast Neoplasms Male03 medical and health sciencesBreast cancerSDG 3 - Good Health and Well-beingBRCA1/2Journal ArticleCarcinomamedicineHumansGenetic Predisposition to DiseasePolymorphismeducationAgedNeoplasm StagingBRCA2 Proteinbusiness.industryOdds ratiohistologic grademedicine.diseaseConfidence intervalMale breast cancer030104 developmental biologyddc:161HomesMutationcancer researchpathologyBRCA1/2; Genotype-phenotype correlations; Histologic grade; Male breast cancer; Pathology; Adult; Aged; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Breast Neoplasms Male; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism Single Nucleotide; Oncology; Cancer Researchbusiness
researchProduct

4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).

2007

Various studies have been published in Italy regarding the different BRCA1 mutations, but only the BRCA1-5083del19 mutation is recurrent and specific to individuals of Italian descent with a founder effect on the Calabrian population. In our previous study, BRCA1-5083del19 mutation carriers were found in four index cases of 106 Sicilian patients selected for familial and/or hereditary breast/ovarian cancers. The high frequency rate of this mutation identified in the Sicilian population led us to perform haplotype analysis in all family carriers. Five highly polymorphic microsatellite markers were used (D17S1320, D17S932, D17S1323, D17S1326, D17S1325) to establish whether or not all these fa…

MaleBRCA1 gene Founder mutation Haplotype analysis Hereditary breast and ovarian cancer Sicilian patientsSettore MED/06 - Oncologia MedicaGenetic counselingPopulationDNA Mutational AnalysisGenes BRCA1Single-nucleotide polymorphismBreast NeoplasmsBiologyBRCA1 geneHaplotype analysiHumansAlleleeducationAllelotypeFounder mutationSicilyGeneticsOvarian Neoplasmseducation.field_of_studyHaplotypeHematologylanguage.human_languageFounder EffectPedigreeOncologyHaplotypesHaplotype frequencylanguageFemaleSicilianGene DeletionFounder effectGenetic counselingMicrosatellite Repeats
researchProduct

Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene

2016

Male breast cancer (MBC) is a rare disease whose etiology appears to be largely associated with genetic factors. BRCA1 and BRCA2 mutations account for about 10% of all MBC cases. Thus, a fraction of MBC cases are expected to be due to genetic factors not yet identified. To further explain the genetic susceptibility for MBC, whole-exome sequencing (WES) and targeted gene sequencing were applied to high-risk, BRCA1/2 mutation-negative MBC cases.Germ-line DNA of 1 male and 2 female BRCA1/2 mutation-negative breast cancer (BC) cases from a pedigree showing a first-degree family history of MBC was analyzed with WES. Targeted gene sequencing for the validation of WES results was performed for 48 …

MaleCancer ResearchDNA Mutational AnalysisBreast NeoplasmsBreast Neoplasms MaleDNA Mutational AnalysiGenetic susceptibility; Male breast cancer; N-acetyltransferase 1 (NAT1); Partner and localizer of BRCA2 (PALB2); Whole-exome sequencing; Oncology; Cancer ResearchGenetic susceptibilityHumansExomeGenetic Predisposition to DiseaseN-acetyltransferase 1 (NAT1)genetic susceptibility; male breast cancer; N-acetyltransferase 1 (NAT1); partner and localizer of BRCA2 (PALB2); whole-exome sequencing; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Breast Neoplasms Male; Case-Control Studies; DNA Mutational Analysis; Exome; Fanconi Anemia Complementation Group N Protein; Female; Genetic Predisposition to Disease; Humans; Italy; Male; Mutation; Nuclear Proteins; Pedigree; Tumor Suppressor Proteins; Oncology; Cancer ResearchNuclear ProteinBRCA2 ProteinTumor Suppressor ProteinBRCA1 ProteinTumor Suppressor ProteinsPartner and localizer of BRCA2 (PALB2)Nuclear ProteinsPedigreeMale breast cancerItalyOncologyCase-Control StudiesWhole-exome sequencingMutationFemaleCase-Control StudieFanconi Anemia Complementation Group N ProteinBreast NeoplasmHuman
researchProduct

Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy

2015

Increasing evidence indicates that common genetic variants may contribute to the heritable risk of breast cancer (BC). In this study, we investigated whether single nucleotide polymorphisms (SNPs), within the 8q24.21 multi-cancer susceptibility region and within BC-associated loci widespread in the genome, may influence the risk of BC in men, and whether they may be associated with specific clinical-pathologic characteristics of male BC (MBC). In the frame of the ongoing Italian Multicenter Study on MBC, we performed a case-control study on 386 MBC cases, including 50 BRCA1/2 mutation carriers, and 1105 healthy male controls, including 197 unaffected BRCA1/2 mutation carriers. All 1491 subj…

MaleCancer ResearchPredictive Value of Test8q24.21; BRCA1/2; Clinical-pathologic characteristics; Low-penetrance BC alleles; Male breast cancer; SNPs; BRCA1 Protein; BRCA2 Protein; Biomarkers Tumor; Breast Neoplasms Male; Case-Control Studies; Chi-Square Distribution; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Italy; Linear Models; Logistic Models; Male; Multivariate Analysis; Mutation; Odds Ratio; Phenotype; Predictive Value of Tests; Risk Factors; Chromosomes Human Pair 11; Chromosomes Human Pair 14; Chromosomes Human Pair 8; Chromosomes Human Pair 9; Polymorphism Single Nucleotide; Oncology; Cancer ResearchGene FrequencyRisk FactorsGenotypeOdds RatioMedicineskin and connective tissue diseasesMultivariate AnalysiSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAGeneticsClinical-pathologic characteristicsBRCA1 ProteinClinical-pathologic characteristicHomozygoteLow-penetrance BC allelesPhenotype8q24.21OncologyItalyMale breast cancer8q24.21; BRCA1/2; Clinical-pathologic characteristics; Low-penetrance BC alleles; Male breast cancer; SNPs; Cancer Research; OncologyLinear ModelCase-Control StudieChromosomes Human Pair 9HumanChromosomes Human Pair 8SNPsHeterozygoteLogistic ModelSNPSingle-nucleotide polymorphismPolymorphism Single NucleotideBreast Neoplasms MaleBreast cancerPredictive Value of TestsBRCA1/2Biomarkers TumorSNPHumansGenetic Predisposition to DiseaseAllele frequencyBRCA2 ProteinChromosomes Human Pair 14Chi-Square Distributionbusiness.industryRisk FactorChromosomes Human Pair 11Case-control studyOdds ratiomedicine.diseaseMale breast cancerLogistic ModelsCase-Control StudiesMultivariate AnalysisMutationLinear ModelsbusinessLow-penetrance BC allele
researchProduct

Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?

2007

Various studies have been published in Italy regarding the different BRCA1 mutations, but only the BRCA1-5083del19 mutation is recurrent and specific to individuals of Italian descent with a founder effect on the Calabrian population. In our previous study, BRCA1-5083del19 mutation carriers were found in four index cases of 106 Sicilian patients selected for familial and/or hereditary breast/ovarian cancers. The high frequency rate of this mutation identified in the Sicilian population led us to perform haplotype analysis in all family carriers. Five highly polymorphic microsatellite markers were used (D17S1320, D17S932, D17S1323, D17S1326, D17S1325) to establish whether or not all these fa…

MaleCancer ResearchSettore MED/06 - Oncologia MedicaPopulationBRCA1 breast cancerBreast NeoplasmsBiologyRisk AssessmentAllelotype AnalysisReference ValuesHumansAlleleeducationSicilySequence DeletionOvarian NeoplasmsGeneticseducation.field_of_studyBRCA1 ProteinHaplotypeFounder Effectlanguage.human_languagePedigreeOncologyMutationMutation (genetic algorithm)languageMicrosatelliteFemaleSicilianMicrosatellite RepeatsFounder effect
researchProduct